Search | Clinical Trials Finder

Conditions: Hunter Syndrome
Interventions: Neurobehavioral testing, Visual and auditory assessments; Behavioral · Other
Lead sponsor: Shire; Industry
Eligibility: 32 Months to 18 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obesity, Insulin Resistance, Metabolic Syndrome
Interventions: Guided Imagery, Digital Storytelling; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 14 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mucopolysaccharidosis Type IIIA
Interventions: DNL126; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Oakland, California • Iowa City, Iowa • Chapel Hill, North Carolina + 1 more

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clinically Severe Obesity, Metabolic Complications After Jejunoileal Bypass, Nutritional Complications After Jejunoileal Bypass, Obesity Recidivism, Inadequate Initial Weight Loss, Intestinal Malabsorptive Syndrome, Protein Malnutrition
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fresno, California

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 55 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions: nfant feeding solution; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 6 Months
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome
Interventions: Restorative yoga therapy; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Euvolemic Hyponatremia
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 66
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more

Conditions: Obstructive Sleep Apnea, Sleep
Interventions: Ketone-IQ (1,3 Butanediol); Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PCOS, Diet Modification, Metabolism, Nutrition Disorders
Interventions: Metformin, One-On-One Dietary Instruction, Video Dietary Instruction; Drug · Other
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Septic Shock
Interventions: LB1148, Placebo; Drug
Lead sponsor: Leading BioSciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 23 more

Conditions: Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Interventions: topiramate, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 17 more

Conditions: Stable Angina, Metabolic Syndrome
Interventions: Ranolazine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metabolic Syndrome
Interventions: Supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Jeffrey B. Schwimmer, MD; Other
Eligibility: 18 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: HIV Infections, Hypertriglyceridemia
Interventions: Fenofibrate, Fish Oil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Cincinnati, Ohio + 2 more

Conditions: Recurrent Basal Cell Carcinoma
Interventions: Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Apple Valley, California • Colton, California • Fremont, California + 11 more

Conditions: Obesity
Interventions: Diet plus continuous bouts, Diet plus short bouts, Diet plus moderate lifestyle activity; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Syndrome, Insulin Resistance
Interventions: TA-65, Placebo; Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 35 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Cardiovascular Diseases, Metabolic Syndrome, Obesity, Prediabetes, Mental Health Disorders, Endocrine Dysfunction, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD)
Interventions: Blood Work; Other
Lead sponsor: Clindove Research LLC; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Mucopolysaccharidosis II
Interventions: Genetic HMI-203; Biological
Lead sponsor: Homology Medicines, Inc; Industry
Eligibility: 18 Years to 45 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Zidovudine, Didanosine, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Irvine, California • Washington D.C., District of Columbia • Galveston, Texas

Conditions: Celiac Disease, Gluten Sensitivity, Non-celiac Gluten Sensitivity
Interventions: Bovine colostrum, Placebo; Dietary Supplement
Lead sponsor: Milky Way Life Sciences LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intestinal Disease, Inflammatory Bowel Diseases, Crohn Disease, Ulcer, Celiac Disease
Interventions: SV-3 Capsule Endoscopy; Device
Lead sponsor: Capso Vision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Saratoga, California

Search by objective public record fields.

Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®

Guided Imagery Intervention for Obese Latino Adolescents

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Risk Factors, Costs, and Impacts of ED Boarding

Laparoscopic Revision of Jejunoileal Bypass to Gastric Bypass

Chronic Inflammation and Exercise Responsiveness

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

Yoga for the Treatment of Metabolic Syndrome

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Impact of Exogenous Ketones on Sleep Disruption in Vulnerable Populations

Low Starch Dietary Education Program vs. Traditional Treatment for PCOS

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Physical Activity in the Treatment of Obesity

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.

Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

Bovine Colostrum to Prevent Absorption of Gluten

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System